MAPP Insider Trading Activity and SEC Form 4 Filings
MAPP insider trading summary
No open-market insider purchases or sales of MAP Pharmaceuticals, Inc. (MAPP) have been reported on SEC Form 4 in the past 12 months.
Latest MAPP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 28, 2013 | Anastasios Gianakakos | SVP, Chief Business Officer | Sell | $500K (20,000 @ $25.00) |
| Feb 28, 2013 | Geraldine Henwood | Director | Sell | $250K (10,000 @ $25.00) |
| Feb 1, 2013 | Donald J Kellerman | SVP,Clinical Dev & Med Affairs | Sell | $35K (1,429 @ $24.73) |
| Jan 26, 2013 | Scott Borland | SVP, Neurology Franchise | Sell | $19K (764 @ $24.75) |
| Jan 23, 2013 | Anastasios Gianakakos | SVP, Chief Business Officer | Sell | $743K (30,000 @ $24.76) |
| Jan 23, 2013 | Thomas A Armer | Chief Scientific Officer | Sell | $1.5M (59,620 @ $24.76) |
| Jan 23, 2013 | Timothy S Nelson | President and CEO | Sell | $2.0M (80,000 @ $24.76) |
| Nov 23, 2012 | Geraldine Henwood | Director | Sell | $56K (3,750 @ $15.00) |
| Nov 23, 2012 | Geraldine Henwood | Director | Sell | $22K (1,490 @ $15.00) |
| Nov 1, 2012 | Anastasios Gianakakos | SVP, Chief Business Officer | Sell | $90K (5,767 @ $15.64) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.